2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Journal of the American College of Cardiology

Volumn 72, Issue 24, 2018, Pages 3200-3223

  Das, Sandeep R ^a   Everett, Brendan M ^a   Birtcher, Kim K ^a   Brown, Jenifer M ^a   Cefalu, William T ^a   Januzzi, James L ^a   Kalyani, Rita Rastogi ^a   Kosiborod, Mikhail ^a   Magwire, Melissa L ^a   Morris, Pamela B ^a   Sperling, Laurence S ^a  

^a NONE

Author keywords

ASCVD; cardiovascular risk reduction; diabetes; Expert Consensus Decision Pathway; GLP 1RA; SGLT2 inhibitor; T2D

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EMPAGLIFLOZIN; ERTUGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IPRAGLIFLOZIN; LIRAGLUTIDE; LIXISENATIDE; LOOP DIURETIC AGENT; LUSEOGLIFLOZIN; METFORMIN; PLACEBO; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; SULFONYLUREA DERIVATIVE; TOFOGLIFLOZIN;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ACUTE PANCREATITIS; ARTICLE; BALANITIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CONSENSUS DEVELOPMENT; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC KETOACIDOSIS; DIABETIC RETINOPATHY; DIZZINESS; DRUG SAFETY; DYSPNEA; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; KIDNEY DISEASE; MACROALBUMINURIA; MEDICAL EXPERT; MEDICAL SPECIALIST; MULTICENTER STUDY (TOPIC); NAUSEA; NECROTIZING FASCIITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH PARESIS; TACHYCARDIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; UROSEPSIS; VAGINA CANDIDIASIS; VOMITING; WEAKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PATHWAY; COMPLICATION;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CRITICAL PATHWAYS; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 85058744849     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.09.020     Document Type: Article

References (80)

1. American Diabetes Association. Statistics About Diabetes: American Diabetes Association. Available at: http://www.diabetes.org/diabetes-basics/statistics/. Accessed January 29, 2018.
2. Rawshani, A., Rawshani, A., Gudbjornsdottir, S., Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 377 (2017), 300–301.
3. Professional Practice Committee. Standards of Medical Care in Diabetes-2018. Diabetes Care, 41, 2018, S3.
4. King, P., Peacock, I., Donnelly, R., The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 48 (1999), 643–648.
5. Riddle, M.C., Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 122 (2010), 844–846.
6. Group, A.C., Patel, A., MacMahon, S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
7. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
8. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care 41 (2018), S86–S104.
9. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
10. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
11. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
12. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
13. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
14. Sperling, L.S., Mechanick, J.I., Neeland, I.J., et al. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol 66 (2015), 1050–1067.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
16. Chan, P.S., Oetgen, W.J., Buchanan, D., et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol 56 (2010), 8–14.
17. Wong, N.D., Patao, C., Wong, K., et al. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res 10 (2013), 505–513.
18. Gaede, P., Vedel, P., Larsen, N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
19. Bittner, V., Bertolet, M., Barraza Felix, R., et al. Comprehensive cardiovascular risk factor control improves survival: the BARI 2D Trial. J Am Coll Cardiol 66 (2015), 765–773.
20. Whelton, P.K., Carey, R.M., Aronow, W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71 (2018), e127–e248.
21. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (2014), S1–S45.
22. Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., et al. 2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70 (2017), 1785–1822.
23. Fihn, S.D., Gardin, J.M., Abrams, J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60 (2012), e44–e164.
24. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
25. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
26. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 68 (2016), 1476–1488.
27. Yancy, C.W., Januzzi, J.L. Jr., Allen, L.A., et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 71 (2018), 201–230.
28. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
29. Vallon, V., Thomson, S.C., Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60 (2017), 215–225.
30. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
31. Kosiborod, M., Cavender, M.A., Fu, A.Z., et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
32. Patorno, E., Goldfine, A.B., Schneeweiss, S., et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ, 360, 2018, k119.
33. Udell, J.A., Yuan, Z., Rush, T., et al. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 137 (2018), 1450–1459.
34. Kosiborod, M., Lam, C.S.P., Kohsaka, S., et al. Lower cardiovascular risk associated with SGLT-2i in >400,000 patients: the CVD-REAL 2 study. J Am Coll Cardiol 71 (2018), 2628–2639.
35. Fitchett, D., Inzucchi, S.E., Lachin, J.M., et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol 71 (2018), 364–367.
36. Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37 (2016), 1526–1534.
37. Fitchett, D., Butler, J., van de Borne, P., et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 39 (2018), 363–370.
38. American Diabetes Association. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. Clin Diabetes 36 (2018), 14–37.
39. Mahaffey, K.W., Neal, B., Perkovic, V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137 (2018), 323–334.
40. Raz, I., Mosenzon, O., Bonaca, M.P., et al. DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab 20 (2018), 1102–1110.
41. ClinicalTrials.gov. Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004). Available at: https://clinicaltrials.gov/ct2/show/results/NCT01986881. Accessed August 15, 2018.
42. ClinicalTrials.gov. Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED). Available at: https://clinicaltrials.gov/ct2/show/NCT03315143. Accessed August 15, 2018.
43. Suissa, S., Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?. Diabetes Care 41 (2018), 6–10.
44. Wanner, C., Inzucchi, S.E., Zinman, B., Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 1801–1802.
45. Cherney, D.Z.I., Zinman, B., Inzucchi, S.E., et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
46. Li, D., Wang, T., Shen, S., et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 19 (2017), 348–355.
47. Jabbour, S., Seufert, J., Scheen, A., et al. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 20 (2018), 620–628.
48. Erondu, N., Desai, M., Ways, K., et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38 (2015), 1680–1686.
49. Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
50. Kaptoge, S., Di Angelantonio, E., White, I.R., et al., Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367 (2012), 1310–1320.
51. Inzucchi, S.E., Iliev, H., Pfarr, E., et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME Trial. Diabetes Care 41 (2018), e4–e5.
52. Verma, S., Mazer, C.D., Al-Omran, M., et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137 (2018), 405–407.
53. Fadini, G.P., Avogaro, A., SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5 (2017), 680–681.
54. Baartscheer, A., Schumacher, C.A., Wust, R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60 (2017), 568–573.
55. Uthman, L., Baartscheer, A., Bleijlevens, B., et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61 (2018), 722–726.
56. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
57. Januzzi, J.L. Jr., Butler, J., Jarolim, P., et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol 70 (2017), 704–712.
58. Holman, R.R., Bethel, M.A., Mentz, R.J., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
59. Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
60. Trujillo, J.M., Nuffer, W., Ellis, S.L., GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 6 (2015), 19–28.
61. Margulies, K.B., Hernandez, A.F., Redfield, M.M., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
62. Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
63. Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 20 (2018), 42–49.
64. ClinicalTrials.gov. Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus. Available at: https://clinicaltrials.gov/ct2/show/NCT02465515. Accessed August 15, 2018.
65. Davidson, J.A., Incretin-based therapies: focus on effects beyond glycemic control alone. Diabetes Ther 4 (2013), 221–238.
66. Nauck, M.A., Meier, J.J., Cavender, M.A., et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136 (2017), 849–870.
67. Nauck, M., Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
68. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 (2016), 1834–1844.
69. Avogaro, A., Vigili de Kreutzenberg, S., Fadini, G.P., Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. Curr Diab Rep, 14, 2014, 483.
70. Fye, W.B., Introduction: the origins and implications of a growing shortage of cardiologists. J Am Coll Cardiol 44 (2004), 221–232.
71. Richards, P., Parker, H.E., Adriaenssens, A.E., et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63 (2014), 1224–1233.
72. Martin, S.S., Sperling, L.S., Blaha, M.J., et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol 65 (2015), 1361–1368.
73. Avorn, J., The Psychology of clinical decision making—implications for medication use. N Engl J Med 378 (2018), 689–691.
74. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
75. Frias, J.P., Guja, C., Hardy, E., et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4 (2016), 1004–1016.
76. Wilcox, C.S., Shen, W., Boulton, D.W., et al. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc, 7, 2018, e007046.
77. Marathe, P.H., Gao, H.X., Close, K.L., American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes 9 (2017), 320–324.
78. Hirsh, B.J., Smilowitz, N.R., Rosenson, R.S., et al. Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J Am Coll Cardiol 66 (2015), 184–192.
79. Inzucchi, S.E., Zinman, B., Fitchett, D., et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 41 (2018), 356–363.
80. Cefalu, W.T., Kaul, S., Gerstein, H.C., et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 41 (2018), 14–31.